NCT05080556View on ClinicalTrials.gov

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2027

Conditions
Ovarian CancerRelapsed Ovarian CancerFallopian Tube CancerPeritoneal CancerEndometrioid CarcinomaHigh Grade Serous CarcinomaOvary Cancer
Interventions
DRUG

Carboplatin

Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.

Trial Locations (1)

Unknown

RECRUITING

University College London Hospitals, London

All Listed Sponsors
collaborator

Anticancer Fund, Belgium

OTHER

collaborator

JP Moulton Charitable Foundation

OTHER

collaborator

Barts & The London NHS Trust

OTHER

lead

University College, London

OTHER